

WE WORK FOR HEALTH

MAJOR MILESTONE: U.S. Life Sciences Investments Top $500B+

Pharmaceutical companies are continuing to invest big in America, **pledging more than $582 billion** since 2025. The surge in American-based investment strengthens the future discovery and delivery of life-altering treatment for U.S. patients while benefiting a sector of the economy that America must continue to secure its position in as a world leader. The life science industry supports **more than 4.9 million jobs**, including **226K+ in North Carolina** as of 2022.

IN NORTH CAROLINA

Nation-high number of investment announcements: **Johnson & Johnson's** two new facilities; **Roche's** $2 billion fill-finish biologics plant in Holly Springs; **Novartis's** two new facilities and a site expansion across Durham and Morrisville; **Biogen's** $2 billion manufacturing expansion and modernization in Durham and Wake Counties; **Ypsomed's** first U.S. manufacturing facility in Holly Springs; **Sanner's** new facility in Greensboro

Congress: Protect America's Position As the World Leader in Life Sciences. Oppose Importing Foreign Healthcare Policies & MFN Drug Pricing

Continued sector investment requires a policy environment that encourages innovation and protects American jobs. Global competitors, including China, are closing the gap.

Drug pricing policies like Most Favored Nation threaten America's biotech revolution.

230+ fewer new medicines over 10 years

1.1 million lost jobs

Surrender competitive edge to **China**

Fail to lower patient costs or address the real drivers of rising healthcare costs

Stay up-to-date on the latest life sciences' investment announcements and state-specific industry impact at weworkforhealth.org/investinamerica and weworkforhealth.org/in-the-states.